Stefanie Riesenberg

Stefanie Riesenberg is a Senior Scientist at Molecular Partners, where involvement focuses on the development of new DARPin therapeutics in the fields of Immune Oncology and Oncology since February 2019. Previously, Stefanie worked as a Senior Scientist in the Target and Pathway Validation division at GlaxoSmithKline Pharma GmbH from May 2016 to December 2018, contributing to target selection through genetic evidence and Functional Genomics approaches. Prior experience includes a PhD at University Hospital Bonn, where research concentrated on transcription factor networks in melanoma cells from August 2011 to March 2016. Stefanie Riesenberg holds a PhD in Oncology and Cancer Biology from The University of Bonn, a Master of Science in Molecular Medicine from The University of Göttingen, and a Bachelor of Science in Molecular Medicine also from The University of Göttingen.